Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

被引：27

作者：

Nooka, Ajay K. ^{[1
]}

Weisel, Katja ^{[2
]}

van de Donk, Niels W. C. J. ^{[3
]}

Routledge, David ^{[4
,5
]}

Otero, Paula Rodriguez ^{[6
]}

Song, Kevin ^{[7
]}

Quach, Hang ^{[8
]}

Callander, Natalie ^{[9
]}

Minnema, Monique C. ^{[10
]}

Trudel, Suzanne ^{[11
]}

Jackson, Nicola A. ^{[12
]}

Ahlers, Christoph M. ^{[13
]}

Im, Ellie ^{[14
]}

Cheng, Shinta ^{[15
]}

Smith, L. ^{[15
]}

Hareth, Nahi ^{[16
]}

Ferron-Brady, Geraldine ^{[13
]}

Brouch, Maria ^{[13
]}

de Oca, Rocio Montes ^{[13
]}

Paul, Sofia ^{[13
]}

Holkova, Beata ^{[13
]}

Gupta, Ira ^{[13
]}

Kremer, Brandon E. ^{[14
]}

Richardson, Paul ^{[17
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, D-20246 Hamburg, Germany

[3] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Dept Hematol, NL-1081 HV Amsterdam, Netherlands

[4] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia

[5] Royal Melbourne Hosp, Melbourne, Vic 3000, Australia

[6] Clin Univ Navarra Pamplona, Ctr Invest Med Aplicada, Navarra 31008, Spain

[7] Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada

[8] Univ Melbourne, St Vincents Hosp Melbourne, Dept Haematol, Melbourne, Vic 3065, Australia

[9] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA

[10] Univ Med Ctr Utrecht, Dept Hematol, NL-3584 CX Utrecht, Netherlands

[11] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Dept Med, Toronto, ON M5G 2C1, Canada

[12] GlaxoSmithKline, Stockley Pk, London, England

[13] GlaxoSmithKline, Upper Providence, PA 19426 USA

[14] GlaxoSmithKline, Waltham, MA 02451 USA

[15] SpringWorks Therapeut, Stamford, CT 06902 USA

[16] Karolinska Univ Hosp, Dept Med, SE-17176 Stockholm, Sweden

[17] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02215 USA

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 16期

关键词：

antibody-drug conjugate; BCMA; belantamab mafodotin; clinical trial; dostarlimab; feladilimab; GSK3174998; multiple myeloma; nirogacestat; platform study;

D O I：

10.2217/fon-2020-1269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received >= 4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma.

引用

页码：1987 / 2003

页数：17

共 50 条

[1] DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).
Richardson, Paul G.
Biswas, Swethajit
Holkova, Beata
Jackson, Nicola
Netherway, Thelma
Paul, Sofia
Ferron-Brady, Geraldine
Yeakey, Anne
Shelton, Chris
de Oca, Rocio Montes
Ahlers, Christoph Matthias
Ballas, Marc S.
Paul, Elaine Marie
Gupta, Ira
Opalinska, Joanna
Luptakova, Katarina
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[2] Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Nooka, Ajay
Quach, Hang
Trudel, Suzanne
Routledge, David
Song, Kevin
Nahi, Hareth
Paul, Sofia
Khan, Josephine
Brouch, Maria
Ferron-Brady, Geraldine
Yeakey, Anne
Shelton, Chris
de Oca, Rocio Montes
Smith, L. Mary
Im, Ellie
Ahlers, Christoph M.
Paul, Elaine M.
Holkova, Beata
Gupta, Ira
Kremer, Brandon E.
Rodriguez-Otero, Paula
BLOOD, 2020, 136
[3] DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)
Richardson, Paul G.
Trudel, Suzanne
Callander, Natalie S.
Nooka, Ajay
Song, Kevin
Uttervall, Katarina
Minnema, Monique C.
Rodriguez-Otero, Paula
Struemper, Herbert
Yeakey, Anne
de Oca, Rocio Montes
Smith, L. Mary
Jackson, Nicola
Kaisermann, Morrys
Im, Ellie
Basile, Frank G.
Ahlers, Christoph M.
Holkova, Beata
Gupta, Ira
Kremer, Brandon E.
Quach, Hang
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S156 - S156
[4] Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Biswas, Swethajit
Holkova, Beata
Jackson, Nicola
Netherway, Thelma
Bao, Weichao
Ferron-Brady, Geraldine
Yeakey, Anne
Shelton, Chris
De Oca, Rocio Montes
Ahlers, Chris
Franco, Sonia
Ballas, Marc
Paul, Elaine
Luptakova, Katarina
Gupta, Ira
Opalinska, Joanna
BLOOD, 2019, 134
[5] DREAMM-5 platform trial: Belantamab Mafodotin (GSK2857916; belamaf; BLENREP) in combination with five different novel agents in patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Weisel, K.
Richardson, P. G.
Trudel, S.
Callander, N.
Nooka, A.
Song, K.
Uttervall, K.
Minnema, M. C.
Rodriguez-Otero, P.
Struemper, H.
Yeakey, A.
de Oca, Montes R.
Smith, L. M.
Jackson, N.
Kaisermann, M.
Im, E.
Basile, F. G.
Ahlers, C. M.
Holkova, B.
Gupta, I
Kremer, B. E.
Quach, H.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 204 - 205
[6] Belantamab mafodotin for relapsed or refractory multiple myeloma
David Gil-Sierra, Manuel
del Pilar Briceno-Casado, Maria
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (06) : 1375 - 1380
[7] Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.
Lonial, Sagar
Grosicki, Sebastian
Hus, Marek
Song, Kevin W.
Facon, Thierry
Callander, Natalie Scott
Ribrag, Vincent
Uttervall, Katarina
Quach, Hang
Vorobyev, Vladimir I.
Min, Chang Ki
Cheng, Shinta
Smith, L. Mary
Yu, Jing
Collingwood, Therese
Holkova, Beata
Kremer, Brandon
Gupta, Ira
Richardson, Paul G.
Minnema, Monique C.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
Nooka, Ajay K.
Stockerl-Goldstein, Keith
Quach, Hang
Forbes, Adam
Mateos, Maria-Victoria
Khot, Amit
Tan, Alan
Abonour, Rafat
Chopra, Bikramjit
Rogers, Rachel
Ferron-Brady, Geraldine
Davidge, Jacqueline
Frey, Steve
Yeakey, Anne
Talekar, Mala
Luptakova, Katarina
Gupta, Ira
Popat, Rakesh
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
Sheikh, Semira
Lebel, Eyal
Trudel, Suzanne
FUTURE ONCOLOGY, 2020, 16 (34) : 2783 - 2798
[10] DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
Callander, Natalie S.
Ribrag, Vincent
Richardson, Paul G.
Nooka, Ajay K.
Song, Kevin
Uttervall, Katarina
Minnema, Monique C.
Weisel, Katja
Quach, Hang
Min, Chang-Ki
Ballas, Marc S.
Li, Xiao fang
Ratia, Nirav
Kaisermann, Morrys
Holkova, Beata
Tudel, Suzanne
BLOOD, 2021, 138

← 1 2 3 4 5 →